|
|
|
|
|
|
|
|
Dr. Jeffrey Shuster received his Ph.D. in genetics from the University of Washington, Seattle, studying the yeast cell cycle under Dr. Lee Hartwell. He joined Metabolon as director, diagnostics development in 2008. Prior to Metabolon, Dr. Shuster served as president of an entrepreneurial start-up diagnostics company, Teotten Diagnostics, aimed at diagnostics of hospital acquired infections. His experience also includes technical management and business development at Paradigm Genetics, work with Novo Nordisk (now Novozymes) in the applications of biotechnology to the production of industrial enzymes, and expertise in diagnostics for Hepatitis C and HIV AIDS with Chiron Corporation (now Novartis). Dr. Shuster has over 40 scientific publications and over 30 issued patents.
|
|
Metabolomics to Advance Drug Discovery
Jeffrey Shuster, Metabolon
Metabolon has developed a metabolomics technology that allows the quantitative measurement and identification of the repertoire of biochemicals contained in a biological sample. The integration of metabolomics data, through its biochemical context with proteomic, transcriptomic and genomic data is one of the aspects that make metabolomics data so useful.
We have used this technology to identify drug mechanism of action (MOA); to find toxicities in marketed drugs and new chemical entities in development, and to identify biomarkers for disease leading to development of new drug targets. The discussion will cover an introduction to the technology of metabolomics and a summary of results from several successful client commercial projects and internal diagnostic projects.
|
|
|
|
|
|
|
|
|
|
|
